Globenewswireยท2025-07-17 05:00Core Points - Sanofi has extended its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation at a price of $129.00 per share in cash, plus contingent rights for additional payments of up to $6.00 per share based on specified milestones [1][2] - The expiration date for the tender offer has been moved to 17:00 EDST on July 17, 2025, from the previous date of July 16, 2025 [2] - As of July 16, 2025, approximately 29,742,419 shares, or 45.85% of Blueprint's total outstanding shares, have been validly tendered, with an additional 23,400,152 shares tendered by notice of guaranteed delivery, representing 36.08% of the outstanding shares [3] Offer Details - The tender offer is subject to conditions outlined in the offer to purchase, including the requirement for a majority of Blueprint's outstanding shares to be tendered [5] - The offer is being managed by Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, and Innisfree M&A Incorporated is acting as the information agent for the offer [4][6] Company Background - Sanofi is a research and development-driven biopharmaceutical company focused on improving lives through innovative medicines and vaccines, leveraging its understanding of the immune system [7]